Novo Holdings A/S

Q2 2024 13F Holdings Report, Restatement, Stock Holdings

Signature - Title
Barbara Fiorini Due - General Counsel
Location
Hellerup, Denmark
Holdings as of
30 Jun 2024
Value $
$1,854,897,213
Num holdings
38
Filing time
20 Aug 2024, 09:29:58 UTC
Form type
13F-HR/A-1 - Restatement
Description
All US holdings of this investor are reported in this report. Top holdings included VTI, BN, TEM, ASML, and CRM.
Previous filing
Q1 2024 - 15 May 2024
Next filing
Q3 2024 - 24 Oct 2024
SEC
View on sec.gov
Sym Weight Trade Impact Company Class Share Change Activity Value Change $ Value $ * Price $ Shares Principal
Filing 2024 Q2 - Restatement compared to 2024 Q1 by default. Changes are calculated vs the previous SEC filing.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
Barbara Fiorini Due General Counsel Hellerup, Denmark 20 Aug 2024

Explanatory Note: This Amendment No. 1 restates the Form 13F Holdings Report filed by Novo Holdings A/S on August 14, 2024. This Amendment No. 1 (i) corrects data in the Information Table relating to the reported position in Evotec AG and Exscientia plc by removing the positions, (ii) corrects data in the Information Table relating to the reported position in Marqeta Inc by inserting 2419738 in Column 5 "VALUE" (iii) corrects data in the Information Table relating to the reported position in Viridian Therapeutics Inc by inserting 26020000 in Column 5 "VALUE", (iv) includes a position in Vanguard Index FDS, and (v) corrects the Report Summary by inserting $1,854,897,213 as the "Form 13F Information Table Values Total".